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Abstract
Viral infections remain a major threat to public health. The speed with which viruses are evolving drug-
resistant mutations necessitates the further development of antiviral therapies with a large emphasis on drug
discovery. To facilitate these efforts, there is a need for robust, high-throughput assays that allow the screening
of large libraries of compounds, while enabling access to detailed kinetic data on their antiviral activity. We
report here the development of a droplet-based microfluidic platform to probe viral fusion, an early critical
step in infection by membrane-enveloped viruses such as HIV, Hepatitis C, and influenza. Using influenza A,
we demonstrate the measurement of the kinetics of fusion of virions with target liposomes with sub-second
temporal resolution. In analogy with acidification of the endosome that triggers fusion in a cellular context, we
acidify the content of aqueous droplets containing virions and liposomes in situ by introducing acid from the
dispersed phase and visualize the kinetics of fusion by using fluorescent probes.
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Viral infections remain a major threat to public health. The speed with which
viruses are evolving drug-resistant mutations necessitates the further development
of antiviral therapies with a large emphasis on drug discovery. To facilitate these
efforts, there is a need for robust, high-throughput assays that allow the screening
of large libraries of compounds, while enabling access to detailed kinetic data on
their antiviral activity. We report here the development of a droplet-based micro-
fluidic platform to probe viral fusion, an early critical step in infection by
membrane-enveloped viruses such as HIV, Hepatitis C, and influenza. Using influ-
enza A, we demonstrate the measurement of the kinetics of fusion of virions with
target liposomes with sub-second temporal resolution. In analogy with acidification
of the endosome that triggers fusion in a cellular context, we acidify the content of
aqueous droplets containing virions and liposomes in situ by introducing acid from
the dispersed phase and visualize the kinetics of fusion by using fluorescent probes.
VC 2016 AIP Publishing LLC. [http://dx.doi.org/10.1063/1.4943126]
I. INTRODUCTION
Droplet-based microfluidics, in which droplets of sub-nanoliter volumes are generated and
used as individual chemical reactors, has allowed a wide range of biomedical applications1
such as digital polymerase chain reaction (PCR),2 rapid pathogen detection,3 and antibiotics
screening.4 Droplet-based microfluidic approaches promise increased throughput, reduced usage
of reactants, and the ability to rapidly execute complex workflows involving multiple steps. In
droplet-based approaches, droplets are dispersed in an immiscible carrier fluid (an oil phase for
aqueous droplets), which prevents evaporation of the droplet and enables easy transport and
manipulation.5 The constant droplet size (reaction volume) and uniform concentration of oil-
insoluble reactants within the droplet allow reactions to be performed with a high level of con-
trol and reproducibility. The development of technology to rapidly generate large numbers of
droplets with uniform size has resulted in novel strategies to perform reactions in a high-
throughput fashion.6
One field of research that has benefitted from such high-throughput approaches is the iden-
tification of biologically active compounds in disease mechanisms.7,8 Using microdroplets as
reaction vessels and controlling them in microfluidic structures opens the possibility of develop-
ing assays that combine high-throughput approaches with the mechanistic insight that tradition-
ally is reserved for biochemical studies.6 To increase the availability of methods that provide
highly detailed kinetic and mechanistic information in a high-throughput fashion, we report
here the development of a droplet-based microfluidic platform that allows the external trigger-
ing and real-time visualization of a pharmaceutically relevant process. In particular, we provide
a proof of principle based on the visualization of the fusion kinetics of the influenza A virus
with a target lipid vesicle.
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Influenza, commonly called the flu, is a highly contagious infection of the upper respiratory
tract and is estimated to be responsible for 250 000–500 000 deaths each year.9 The recent
emergence of new, highly virulent porcine (H1N1) and avian (H5N1) strains underscores the
difficulty we have as a society in addressing this public-health threat. Currently, there are two
classes of antiviral drugs that are effective against influenza: M2 inhibitors, including amanta-
dine and rimantadine, and the neuraminidase inhibitors Tamiflu and Relenza.10 Most circulating
influenza strains are resistant to the former class of drugs, and Tamiflu-resistant strains of
H5N1 have recently emerged. Additionally, no vaccine has been developed yet that provides
lasting protection against influenza infection. Therefore, there is a great need for new antiviral
drugs and vaccines and for experimental tools to develop these therapeutics.
The first key molecular event during the infection cycle of membrane-enveloped viruses,
such as influenza, is the fusion of the viral lipid bilayer with the cellular membrane. The fusion
process represents an attractive target for antiviral therapeutics, but currently only one antiviral
drug that targets fusion—enfuvirtide, which targets human immunodeficiency virus (HIV)
fusion—is commercially available.11 Treatment of HIV with combinations of drugs that target
different steps in the viral lifecycle has been successful in slowing the emergence of drug re-
sistance. Influenza antiviral treatments could similarly benefit from “drug cocktails,” which will
require the development of new classes of therapeutics.
Among the barriers to the development of useful fusion inhibitors is the difficulty in
designing a suitable assay that allows both parallel screening of multiple compounds and access
to quantitative and mechanistic information, especially in cases where a structure-based molecu-
lar assay is not feasible. Conventional assays are generally based on single or multicycle virus
growth curves that take multiple days to complete and provide little information on the mode
of inhibition.12 Here, we report a method that combines highly quantitative fluorescence meth-
ods with the external control of fusion reactions inside microdroplets as a novel tool to screen
for and characterize new antiviral compounds. We demonstrate our droplet-based assay for two
strains of influenza virus, which differ in terms of their fusion proteins. In this study, we show
that both viral particles remain functional within microdroplets. We then use one of these
strains as a model system to extract fusion kinetics and demonstrate the action of a neutralizing
antibody.
II. MATERIALS AND METHODS
A. Chip design and the pH switch
We use a 8 10 mm2 microfluidic chip fabricated from poly(dimethylsiloxane) (PDMS)
using standard soft-lithography techniques. The width and height of the main channel are 45
and 100 lm, respectively. The oil used in this study is fluorinert-based oil with PEG-PE as the
surfactant (See supplemental material at for more details).13 The device consists of three sec-
tions: a droplet generator, a pH switch, and observation cavities (Figure 1(a)). The droplet
generator consists of a head-on structure to generate aqueous droplets in the oil phase. Fluid
pressures of the aqueous and oil phase of droplet generation module are 10 and 8 mbar,
respectively.
The microfluidic chip is equipped with a structure that introduces droplets to a new chemi-
cal environment, allowing for in situ adjustment of the pH of the aqueous droplets.14 The pH
switch consists of a junction where a second oil phase containing an acid (acetic acid) that is
both soluble in oil and water is mixed with the carrier oil in the main channel, allowing the
acid to come into contact with the droplet and subsequently acidify its aqueous interior (Figure
2(a)). To achieve a pH of 5.9 in the droplets after the pH switch, acidic oil with an acid-to-oil
ratio of 5.5 104% (by volume) was used at the switch with a positive pressure of 5 mbar at
its inlet.
The third section of the microfluidic chip contains a 48-mm long, serpentine-shaped flow
channel that allows the droplets to stay within the confines of the chip for periods up to 8 s,
allowing prolonged observation of the fusion reactions taking place within the droplets. The ser-
pentine delay line contains periodically spaced cavities to transiently reduce the speed of a
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droplet to allow capturing of its fluorescence signal on a CCD camera and minimize blurring
by motion.
A wide-field fluorescence microscope is used to visualize the droplet fluorescence in the
microfluidic structure. The microscope is equipped with a 2/0.08 NA objective, a custom-
ordered microscope filter cube (Chroma Ltd. filters zet488/561 m and zt488/561rpc) and AVT
Prosilica GX6600 camera. The home-built microscope is equipped with dual color lasers,
488 nm and 561 nm (Sapphire models, Coherent, Inc.) for visualization of both R18-labeled
viruses and pH-sensitive fluorescein. The camera is controlled by Vimba 1.3 imaging software.
B. Virus, liposome, and proteo-liposome preparation
Two strains of influenza were used in this study, namely, A/Puerto Rico/8/34 (PR8) and A/
HKX31 (X31). In our assay, functionalized liposomes were used as the host. To accommodate
for the different surface proteins expressed at the viral surface (H3N2 for X31 and H1N1 for
PR8), we engineered liposomes containing phosphatidylcholine (PC) and cholesterol supple-
mented with 1% Gd1A for X31 experiments and the sialoglycoprotein glycophorin A (GypA)
FIG. 1. (a) Schematic of the microfluidic channel used in the droplet-based viral fusion assay. The components include a
droplet generator, a pH switch, a micromixer, and detection cavities. The inset shows the pH switch, a structure that allows
the rapid drop of droplet pH by introducing oil with an acid that is soluble in both the oil and aqueous phases. (b) The
dimensions of the entire microfluidic device are 8 mm 10 mm. (c) Schematic of the experimental assay. In this assay,
droplets act as reaction chambers in which virus and receptor carrying liposome (host membrane mimic) fuse upon acidifi-
cation. This process is visualized by fluorescence microscopy.
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for PR8 experiments. To prepare liposomes, lipids (DOPC:Cholesterol:gd1a/80:19:1 molar ra-
tio) dissolved in chloroform were mixed and the chloroform was subsequently removed by ar-
gon flow followed by vacuum desiccation for 0.5–1.0 h. Subsequently, the lipid mixtures were
suspended in HNE buffer (5 mM HEPES, 140 mM NaCl, 0.1 mM EDTA, pH 7.4). Next, the so-
lution was exposed to repeated freeze/thawing cycles and extruded using polycarbonate mem-
brane filters having a 100-nm pore diameter (Avanti Polar Lipids).
Proteoliposomes containing GypA (full-length with a GST tag, Abnova, Taipei City,
Taiwan) were produced by mixing lipids solubilized in detergent with the GypA.
Proteoliposomes were formed by removal of detergent with Bio-Beads (SM-2 absorbent, Bio-
Rad Laboratories, Inc.).
C. Viral fusion reaction mixture
For the fusion assay, we mixed the liposome preparation with viral particles previously la-
beled with octadecyl rhodamine B chloride (R18). In order to label viruses, viral particles were
first mixed with R18 (Figure S1) for 3 h in the dark. The viruses were then purified from the
excess of dye by a PD10 size-exclusion column before use in the viral fusion experiments. We
used a virus-liposome ratio of at least 1–10 to ensure an excess of liposomes compared to
viruses in each droplet. After 30 min of incubation, which results in the virus binding to lipo-
somes (Figure S2), the mixture (initial pH 7.4) was injected into the droplet-generating module.
Before the injection of the mixture into the microfluidic chip, the pH-sensitive fluorescein (fluo-
rescent above its pKa of 6.4 and non-fluorescent below this value) was added to the mixture,
with a final concentration of 2 lg/ml. To perform a fusion inhibition experiment, we mixed
FIG. 2. (a) Fluorescence images of droplets inside the microfluidic channel (top), obtained from positions as indicated in
the lower panel. Position F shown in the channel layout is the point at which acidification is applied. The time correspond-
ing to this position is set to t¼ 0. (b) The monitored fluorescence emission of selection (A), shown in panel (a), over time.
Each peak represents a single droplet. The detected signal originates from fluorescein-labeled droplets. (c) Intensity of the
fluorescein in the droplets at different time points (positions) in the microfluidic channel. The decrease in the fluorescence
intensity at t¼ 0 s is due to the arrival of acidic oil from the pH switch in the main channel. Fluorescein at different known
values of pH in the dispersed phase was used in the microfluidic channel with a neutral switch oil to generate the calibration
curve. Given the initial pH of the aqueous phase and the calibration curve, the pH of the dispersed phase after the pH switch
can be calculated.
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inhibitory antibody with the labeled-virus solution at a final antibody concentration of 1 lM.15
The mixture was pre-incubated before addition of the liposomes and fluorescein.
D. Fluorescence detection of viral fusion
In this assay, the viral membrane is fluorescently labeled with a fluorophore, at a density
sufficiently high to result in fluorescence quenching (Figure 1(c)). Fusion of the viral membrane
with the target lipid bilayer allows the dye in the viral membrane to diffuse into the target
bilayer resulting in a rapid dequenching of the fluorescence.16 For the liposome size used in our
study (100 nm in diameter), fusion leads to an increase in the fluorescence signal with the signal
intensity being larger than the intensity before acidification (Figure S3).
To detect fluorescence from the droplets, we measured the integrated intensity of a selected
region of the main channel at a fixed position (such as selection A in Figure 2(a)) in the droplet
path over time. Figure 2(b) shows an example of droplet detection on a fixed position on the
chip as a function of time. Each peak corresponds to the passage of a droplet through the
selected detection area. To follow the intensity of the droplet content over time, we recorded
the fluorescence intensity of the droplets at different positions. Under the condition of constant
fluid flow and droplet-generation rate, we could assign each position along the flow channel to
a time corresponding to the travel time of the droplets in the channel in the microfluidic chip.
We set the time corresponding to the passage of a droplet from pH-switch to zero. Knowing
the exposure time of the collected data and the position of droplets at any given time, we assign
each position in the channel to a time, with t¼ 0 being at the pH switch.
III. RESULTS
We initially used the X31 strain of influenza A as a model system to observe ganglioside-
mediated viral fusion using our microfluidic droplet platform. We observed generation and
passage of droplets through different modules of the microfluidic chip (Figure 2(a)). After gen-
eration, the droplets were moved to the first imaging section, where we recorded the initial
fluorescence signal of the droplet (Figure 2(b)). Next, the droplets were transferred to the pH
controller (switch), where we observed a sudden drop in the intensity of the fluorescein inside
the droplets, consistent with a drop in the pH. Figure 2(c) shows that the fluorescence of fluo-
rescein decreases at t¼ 0, which corresponds to the position of the pH switch. After pH adjust-
ment, the droplets were then slowed down by their passage through detection cavities, where
the fluorescence of droplets was monitored over time. Figure 3(a) illustrates the fusion of X31
with a liposome by monitoring the fluorescence of the R18 signal of the droplets (see also
Figures S4 and S5). Upon viral fusion with liposomes, we detect an increase in the signal of
viruses caused by the de-quenching of R18 dye.
Similarly, we performed the assay on the PR8 strain of influenza A, a virus that fuses more
efficiently when using a glycophorin protein receptor.17 The proteoliposomes used as the host
model in this assay were mixed with R18-labeled virus particles, and the mixture was used to
FIG. 3. (a) Intensity of R18-labeled viruses in droplets over time. (b) Fusion rate as a function of pH. At low pH, the rate is
nearly independent of pH. At high pH values, the fusion rate decreases with the increase in pH. Lines are a guide to the
eye. (c) Time profiles of fluorescence intensity from R18 labeled viruses compared for viral fusion assays in the presence
(red) and the absence (blue) of antibody.
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generate aqueous droplets. The rest of the workflow was identical to the experiments described
above using the X31 strain. A similar increase in fluorescence of the R18 dye was observed for
PR8, as shown in Figure S6. These results show that the glycophorin protein receptor as well
as PR8 virus are functional in the droplet-based platform.
Our setup enables a detailed kinetic characterization of the pH-dependent fusion of influ-
enza with liposomes. To demonstrate this capability, we studied fusion of the X31 strain of
influenza A for a number of pH values in the range of 3.5–6. Fusion of viral envelope and host
membrane involves multiple kinetic barriers. The two membranes have to overcome the hydra-
tion force that prevents them from approaching each other. After coming into direct contact,
the two bilayers have to deform to form a hemifusion stalk. Finally, there is a barrier associated
with conversion of a hemifusion stalk to a progressively expanding pore.18,19 The envelope pro-
tein that mediates fusion, the hemagglutinin (HA) protein, is responsible for the catalysis of
each of these three steps. Upon acidification, the protein complex undergoes a conformational
change, which results in the formation of a long coiled-coil segment capable of penetrating a
hydrophobic fusion peptide into host membrane. After binding, the protein complex folds back
in a stochastic manner, a movement that forces the two membranes together.20–23
The timescale between acidification and hemifusion is determined by several factors, such
as the size of the energy barrier to be overcome and the ability of the protein to coordinate its
refolding with the collapse of neighboring HAs. To extract kinetic information, we measured
the temporal profile of the fluorescence of the R18 of the X31 membrane for each pH value
(Figure 3(b)). The probability distribution of the time intervals can be described by a gamma
function. We extracted rate constants by fitting these time profiles with an integral of the
gamma function (see supplemental material for more detail).13,24 The results are presented in
Figure 3(b) in which multiple pH regimes can be identified. There is a pH regime in which the
fusion kinetics of X31 are not affected. At lower pH values, acidity results in faster kinetics.
The optimal pH is approximately 5, corresponding to the fastest hemifusion kinetics. The
observed trends in Figure 3(b) are in excellent agreement with the previous reports.25
This platform can be readily adapted to study the effect of antiviral drugs on the kinetics
of viral fusion. To illustrate this point, we studied inhibition of X31 viral fusion by a
hemifusion-neutralizing antibody (Ab). The IgG antibody used in this study targets a conserved
region in the stem region of HA and thereby inhibits influenza A HA-mediated membrane
fusion. We first pre-incubated the antiviral antibody with the virus preparation and then added
liposomes to the mixture. After incubation, the sample was used as the dispersed phase in our
platform. When compared to our observations in the absence of Ab, setting the pH of the drop-
let to an acidic pH resulted in a less pronounced increase in the R18 fluorescence. We used a
ratio of [virus]/[Ab] that completely prevents the rise in R18 fluorescence. Figure 3(c) compares
the full inhibition of the X31 virus due to the presence of antibody with the X31 fusion experi-
ment in the absence of the antibody.
IV. DISCUSSION
In this report, we describe the observation of viral fusion within emulsion droplets. The tra-
ditional in vitro approach to study viral fusion is by measuring lipid mixing, an approach that
we adapted to our droplet-based platform. In our droplet-based assay, the observed increase in
the R18 fluorescence can be attributed to fusion of the viral membrane with the liposome.
Similarly, in traditional bulk liposome assays a rise in R18 fluorescence can be seen upon acidi-
fication. The fusion allows R18 (a self-quenching dye) to diffuse from the viral membrane to
the host membrane. This dilution leads to dequenching and thus to an increased emission. We
observed this pH-dependent dequenching for two strains of Influenza A (X31 and PR8), indicat-
ing that both viruses retain their integrity and fusogenicity in the oil/water emulsion. The meas-
ured fusion kinetics agree well with the previous reports based on single-particle and ensemble
studies,25–30 where conventional oil-free systems were used.
Our droplet-based technique provides a number of advantages over bulk assays to monitor
viral fusion, including increased throughput, reduced reagent use, and fast mixing needed for
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kinetic analysis. Viral fusion is a rapid process and fast pH change, as provided by our droplet-
platform, is needed for reliable monitoring of the kinetics of the reaction. Mixing a large vol-
ume in a conventional dequenching assay may give rise to an asynchronous triggering, and the
resulting poorly defined timing of the pH drop may mask the magnitude of the pH dependence
of fusion. Therefore, to facilitate a rapid distribution of the acid throughout the cuvette, rapid
mixing of contents is needed. However, rapid mixing results in shearing and may disrupt virus
binding. We have overcome this limitation by using the on-chip pH switch module and small
droplet volumes, providing a rapid pH change in our reaction chamber (droplet).
Introducing viral fusion assays into droplet microfluidics presents both challenges and
opportunities. One challenge is to design the chemistry of the aqueous and oil phases in a way
that maintains the functionality of the reactants. Care has to be taken when designing the
experiments so that incorporated viruses and membranes do not penetrate the oil phase and pre-
serve their native structure. Adsorption of biological material to the interface also affects drop-
let stability.31,32 Another important requirement is a detection technology that allows a suffi-
ciently high signal-to-noise ratio to detect and analyze viral fusion at the level of individual
droplets. In addition, the detection protocol has to be sufficiently rapid to monitor the relatively
fast kinetics of viral fusion. Finally, additional controls may be needed when screening for pre-
viously uncharacterized therapeutics. For example, the antibody used in our study has been pre-
viously characterized,33 and optimal concentration for neutralization15 was known. This is not
the case in screening applications; previously uncharacterized antibodies have to be compared
with non-neutralizing antibodies as well as no-antibody controls.
The usage of Fluorinert FC-40 oil and a biocompatible surfactant (PEGylated-PE) in our
assay ensured the integrity of the reactants. The amount of surfactant used in this assay was
also optimized for droplet stability. A high amount of surfactant leads to the splitting of drop-
lets as they travel along the chip, a process that is caused by roughness of the surface. If the
amount of surfactant is too low, the droplets become prone to splitting at the chemical switch,
a process that is the result of the interaction of biological material with the interface.
The speed of pH adjustment in our study can be increased by introducing a micro-switch
and suppressing material exchange between consecutive droplets.34,35 In the experiments pre-
sented here, the pH of the chemical switch was typically set to a desired pH, followed by the
collection of data from a train of droplets. After rigorous washing, the system was operated at a
new desired pH. One can adjust the pH of the chemical switch with a much higher frequency
using a micro-switch-equipped chemical switch. For certain applications, one might be inter-
ested in adjusting the pH of every single droplet independently to a different pH. The challenge
would then be to make the pH of two consecutive droplets uncorrelated, particularly when the
inter droplet distance approaches the droplet length. A solution to this problem could be the
introduction of an air bubble before and after each aqueous droplet.
V. CONCLUSIONS AND OUTLOOK
Here, we report on the development of a droplet-based viral fusion assay that can be used
for kinetic studies. We demonstrated this platform using two influenza viruses that exploit very
different cell-surface receptors. This general approach can be used to study other similar viruses
such as hepatitis C virus (HCV) and dengue. One can speculate on possible future extensions
of the proposed technology beyond its application in antiviral drug studies. In view of recent
developments in single-cell analysis and sorting, we envision that our assay can be further
expanded to study single-cell interactions with single viral particles.36 This application will
allow studies of not only fusion but also biological processes that follow the infection such as
the changes in the gene expression profile. Furthermore, viruses are used as gene delivery
vesicles for therapeutic purposes and engineering applications such as viral barcoding of cells.
Our droplet-based viral fusion platform can be used for controlled viral barcoding of cells,
which is needed, among others, to study cellular heterogeneity.37 Viral genetic barcoding can
be used to track single cells in heterogeneous populations such as differentiating hematopoietic
stem cells and growing tumors.38,39
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